within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX12_MelanomaVaccine;

model MelanomaVaccine
  extends Pharmacolibrary.Drugs.ATC.L.L03AX12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L03AX12</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>The melanoma vaccine (ATC code L03AX12) refers to various therapeutic cancer vaccines developed to stimulate the immune system to recognize and attack melanoma cells. These vaccines may contain melanoma-associated antigens, autologous or allogeneic melanoma cells, or peptides designed to promote an immune response. As of 2024, there is no universally approved melanoma vaccine for routine clinical practice; use has mainly been limited to clinical trials or experimental settings.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic (PK) or absorption/distribution/clearance parameters have been reported for the melanoma vaccine (ATC code L03AX12) in humans or animals. Cancer vaccines function by inducing immune response rather than acting as conventional pharmacological drugs with plasma concentration profiles, so classic PK (e.g., volume of distribution, clearance, Ka) parameters are generally not applicable. Any numerical PK values given below are estimated placeholders provided for template completeness, not empirically derived.</p><h4>References</h4><ol><li><p>Meneveau, MO, et al., &amp; Slingluff, CL (2021). Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. <i>Journal for immunotherapy of cancer</i> 9(5) –. DOI:<a href=&quot;https://doi.org/10.1136/jitc-2020-002214&quot;>10.1136/jitc-2020-002214</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34035112/&quot;>https://pubmed.ncbi.nlm.nih.gov/34035112</a></p></li><li><p>Leidner, R, et al., &amp; Thompson, JA (2023). First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. <i>Journal for immunotherapy of cancer</i> 11(10) –. DOI:<a href=&quot;https://doi.org/10.1136/jitc-2023-007725&quot;>10.1136/jitc-2023-007725</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37907221/&quot;>https://pubmed.ncbi.nlm.nih.gov/37907221</a></p></li><li><p>Chen, Q, et al., &amp; Du, Y (2023). Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy. <i>Nanomedicine : nanotechnology, biology, and medicine</i> 53 102693–None. DOI:<a href=&quot;https://doi.org/10.1016/j.nano.2023.102693&quot;>10.1016/j.nano.2023.102693</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37343780/&quot;>https://pubmed.ncbi.nlm.nih.gov/37343780</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MelanomaVaccine;
